Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v2-EN
Language French English
Date Updated 2018-08-30 2018-07-27
Drug Identification Number 02016109 02016109
Brand name SURVANTA SURVANTA
Common or Proper name SURVANTA VIAL, 4mL SURVANTA VIAL, 4mL
Company Name ABBVIE CORPORATION ABBVIE CORPORATION
Ingredients BERACTANT BERACTANT
Strength(s) 25MG 25MG
Dosage form(s) SUSPENSION SUSPENSION
Route of administration INTRATRACHEAL INTRATRACHEAL
Packaging size 4mL vial 4mL vial
ATC code R07AA R07AA
ATC description OTHER RESPIRATORY SYSTEM PRODUCTS OTHER RESPIRATORY SYSTEM PRODUCTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2018-07-24 2018-07-24
Estimated end date 2018-09-04 2018-09-03
Actual end date 2018-08-29
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments We are currently monitoring our inventory of Survanta 4mL due to an unexpected increase in market demand. We have normal inventory levels of Survanta 8mL. During that period, orders will be processed to prioritize patient needs. We are currently monitoring our inventory of Survanta 4mL due to an unexpected increase in market demand. We have normal inventory levels of Survanta 8mL. During that period, until September 3, orders will be processed to prioritize patient needs.
Health Canada comments